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TregWe have previously reported that HIV-1 preferentially infects Foxp3+ Treg cells in vitro and in vivo, and
Foxp3 enhances theHIV-1 LTR expression through epigeneticmechanisms in T cells.We report here that histone
deacetylase inhibitor (HDACi) failed to further enhance HIV gene expression in FoxP3+ T cells. We discovered
that Foxp3 inhibited cellular HDAC activity in T cells, and mutations in the forkhead domain that ablate
Foxp3 function also abolished its ability to inhibit HDAC. When co-expressed, Foxp3 speciﬁcally inhibited the
deacetylase activity of HDAC1. We further showed that Foxp3 was associated with HDAC1, and mutations in
the forkhead domain that ablate Foxp3 function in Treg cells also inhibited Foxp3 associationwith and inhibition
of HDAC1. Finally, Foxp3 failed to enhance HIV-1 gene expression in human T cells expressing HDAC1-speciﬁc
shRNA. We conclude that Foxp3 modulates gene expression in human T cells at least partly by inhibiting
HDAC1 activity.77454 to L. S.). The authors de-
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Regulatory T cells (Treg) control autoimmunity induced by neonatal
thymectomy (Sakaguchi et al., 1995). The forkheadwinged-helix family
member FoxP3 is identiﬁed as the essential transcription factor for Treg
development and function (Fontenot et al., 2003; Khattri et al., 2003). In
response to T cell stimulation, Foxp3+CD4+ Treg cells fail to produce
IL-2 or proliferate in vitro. Recent studies have revealed multiple mech-
anisms of Foxp3-mediated repression of the IL-2 gene (Ziegler, 2006).
FoxP3 is reported to interact with the T cell-speciﬁc transcription factor
NFAT to displace the NFAT/AP-1 complex at the IL-2 enhancer (Wu
et al., 2006). A Foxp3/Runx complex binding at a distal IL-2 promoter
region also contributes to Foxp3-mediated IL-2 repression (Ono
et al., 2007).
Although described as a transcriptional repressor of effector cyto-
kines in T cells, Foxp3 also enhances expression of genes associated
with Treg functions (Fontenot et al., 2005; Holmes et al., 2007). Inter-
estingly, Treg cells support higher levels of HIV-1 or FIV infection than
conventional CD4+ T cells in vitro (Joshi et al., 2005; Oswald-Richter
et al., 2004). We have recently reported that in the humanized mouse
model, CD4+FoxP3+ T cells in lymphoid organs are also preferentially
infected by HIV-1 in vivo (Jiang et al., 2008). We have also reported
that HIV gene expression is enhanced in human CD4+T cells ectopically
expressing FoxP3 (Holmes et al., 2007). This enhancement requiresNFκB sites in the LTR, associated with increased histone 3 acetylation
at the LTR (Holmes et al., 2007).
HDAC inhibitors such as TSA repress the IL-2 promoter but enhance
HIV LTR (Laughlin et al., 1993; Moreira et al., 2003), similarly as Foxp3
(Holmes et al., 2007). In this study we report that TSA failed to further
enhance HIV gene expression in Foxp3+ T cells. We showed that
Foxp3 speciﬁcally inhibited the activity of HDAC1. In addition, Foxp3
failed to enhance HIV-1 gene expression in human T cells expressing
HDAC1-speciﬁc shRNA.
Results
Foxp3 modulates HIV-1 gene expression via HDAC-related mechanisms
To determine the role of HDACs in FoxP3-mediated gene regulation,
Jurkat T cells transducedwith control or Foxp3 vector (N95% efﬁciency)
were infected with VSV-g pseudotyped HIV-1 NL4-luciferase reporter
virus. Treatment of these cells at 24 hours post infection with
the HDAC inhibitor TSA resulted in a 5–6 fold increase in HIV-1
gene expression in unstimulated or CD3/CD28 stimulated T cells
(Figs. 1A/B). As we have previously reported (Holmes et al., 2007),
Foxp3 expression also enhanced LTR activity. However, addition of
TSA to FoxP3-expressing human T cells did not further enhance LTR
activity (Figs. 1A/B), suggesting an overlapping role of HDAC inhibition
and FoxP3 in activation of the HIV LTR promoter. We next determined
the repression of IL-2 by TSA and FoxP3. Jurkat cells were transduced
with vector or FoxP3 retrovirus and stimulated with PMA and Ionomy-
cin for 16 hours in the presence or absence of TSA 50 or 200 nM). High
dose TSA inhibited IL-2 expression about 4 fold, to similar levels seen
with Foxp3 expression. In the presence of TSA, FoxP3 marginally
Fig. 1. HDAC inhibitor TSA does not further enhance HIV-1 gene expression in FoxP3-expressing T cells. Jurkat cells transduced with control vector or FoxP3 (N95%) were infected
with VSV-g pseudotyped HIV-NL4-luciferase reporter virus. At 24 hours post infection, cells were left unstimulated (A) or activated (B) with anti-CD3/CD28 mAb, and treated with
mock or TSA for 24 hours. HIV-1 gene expression (luciferase activity) was determined at 48 hpi. Data represent summarized results from N3 experiments. Error bars indicate SD of
triplicate samples, and * indicates pb0.05. (C) Both TSA and FoxP3 inhibit IL-2 gene expression. Jurkat cells are transfected with empty vector or FoxP3 and treated with 50 or
200 nM TSA and activated with PMA and Ionomycin for 16 hours. IL-2 expression in the supernatant was measured. (D) Luciferase driven by the IL-2 promoter was co-transfected
with FoxP3 or control vector in Jurkat cells. Cells were activated, lysed and luciferase was determined. Data represents multiple experiments done in triplicate.
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promoter, Jurkat T cells were transfected with IL-2 luciferase plasmid
in the presence or absence of TSA. FoxP3 inhibited the IL-2 promoter
by 2–3 fold, and TSA similarly inhibited IL-2 promoter. Addition of
both TSA and FoxP3 showed only slight further repression (Fig. 1D).
Therefore the activation of LTR or inhibition of IL-2 by FoxP3 and TSA
is likely through an overlapping pathway.
Foxp3 expression reduces HDAC activity in human T cells
The data above suggest that FoxP3may affect HDAC activity tomod-
ulate gene expression. Utilizing a live cell permeable HDAC substrate,
we ﬁrst measured HDAC activity in puriﬁed human CD4+CD25−
(Th) and CD4+CD25+ (Treg) populations. In resting T cells, both Th
and Treg cells expressed similar low levels of HDAC activity (data not
shown). After activation with CD3 and CD28 antibodies, HDAC activity
was elevated about 5 fold in Th cells. However, the HDAC activity was
lower in activated Treg cells than in Th cells (20–30%, Fig. 2A). Thus pri-
mary human Treg cells had lower HDAC activity. We next determined
the effect of Foxp3 on cellular HDAC deacetylase activity. Foxp3 expres-
sion in Jurkat T cells signiﬁcantly decreased cellular HDAC activity
(about 20%, Fig. 2B). Thus Foxp3 expression was associated with
reduced HDAC activity in human T cells.
To deﬁne the functional domains of Foxp3 required to inhibit
HDAC, a number of Foxp3 mutants with deletion and point mutations
were tested. Interestingly, the WWRR mutant with mutations in the
Foxp3 forkhead domain that inhibit Foxp3/NFAT interaction
and Foxp3 activity (Wu et al., 2006) also was unable to inhibit
HDAC activity (Fig. 2C). The Foxp3 WRR mutant, which has slightlyreduced function in vivo compared to wild type Foxp3, retained
HDAC inhibition activity, albeit slightly lower than wild type Foxp3
(Fig. 2C). To correlate the relative activity in activating HIV-1 gene
expression in T cells, the WRR and WWRR mutants were expressed
and tested in Jurkat T cells infected with HIV-luciferase reporter
virus. Similar to their relative activity to inhibit HDAC activity, HIV
enhancement was also impaired by the WWRR mutations but
not by the WRR mutations (Fig. 2D). Therefore, critical residues in
the forkhead domain of Foxp3 are required for HDAC inhibition, IL2
inhibition and HIV activation by Foxp3.
Foxp3 speciﬁcally inhibits HDAC1 activity
We next determined the speciﬁc HDAC that was inhibited by
Foxp3. Since class I HDACs are responsible for most, if not all, of the
TSA-sensitive HDAC enzymatic activity (Lahm et al., 2007), we
expressed Foxp3 and various class I (HDAC1, 2 and 3) and one class II
HDAC (HDAC4) in 293 T cells. Flag-tagged HDAC1, 2, 3 and HDAC4
were immuno-precipitated from equal amounts of cell lysates in the
presence or absence of Foxp3. HDAC deacetylase activity in the precip-
itates was assessed with an acetylated substrate of class I and II HDACs.
Foxp3 was able to efﬁciently inhibit HDAC1 (~40% inhibition) but not
HDAC 2–4 (Figs. 3A, B). The difference was not due to differences in
HDAC expression or immuno-precipitation efﬁciency, as demonstrated
by Western blot analysis of the IP'ed HDAC1–4 proteins (Fig. 3A). To
conﬁrm that inhibition of HDAC1 occurred in human T cells, Foxp3-
dependent HDAC inhibition was assayed in Jurkat cells expressing
HDAC1 by retroviral transduction. Ectopic expression of HDAC1 in
T cells increased the cellular HDAC activity, and Foxp3 was able to
Fig. 2. Foxp3 inhibits HDAC activity in human T cells. (A) Primary human Th (CD4+CD25−) and Treg (CD4+ CD25+) cells sorted from PBMC's were activated with anti-CD3/CD28
mAb. Cells-associated HDAC activity was assessed with cell permeable HDAC substrate as described in methods. Total cellular HDAC activity in equal number of Th or Treg cells is
presented. Data are representative of 3 independent experiments, each done in triplicate. Error bars indicate SD of triplicate samples, and * indicates pb0.05. (B) Jurkat cells were
transduced with control or Foxp3 vector. Total cellular HDAC activity in equal number of cells is presented. TSA was added to show TSA-sensitive HDAC activity. (C) Foxp3 point
mutants were expressed and HDAC activity was measured. Data represent three independent experiments. (D) FoxP3 WWRR mutant was unable to enhance HIV gene expression
or to inhibit HDAC activity in human T cells. Jurkat T cells transduced (N95%) with wild type, WRR and WWRR mutant Foxp3 genes were infected with NL4-luc reporter virus and
assayed for luciferase activity. Error bars indicate SD of triplicate samples, and * indicates signiﬁcant differences over PG vector (pb0.05).
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bition of HDAC1 activity was not due to reduced HDAC1 expression
or its nuclear translocation, because nuclear levels of HDAC1 in Jurkat
cells were not affected by Foxp3 expression (Fig. 3D).Foxp3 interacts with HDAC1 via critical domains
There are several mechanisms of HDAC regulation, including post-
translational modiﬁcation and association with a multi-subunit pro-
tein complex. We wanted to determine if Foxp3 interacts with
HDAC1 to regulate its deacetylase activity. To test if Foxp3 and HDAC1
are associated in vivo, 293 T cells were transfected with Foxp3 with or
without HDAC1. When HDAC1 was IP'ed with an antibody, Foxp3 was
co-IP'ed (Fig. 4A). Similarly, Foxp3 in Jurkat cells was associated with
endogenous HDAC1 (Fig. 4B). To map the domain of Foxp3 required
for HDAC1 interaction, 293 T cells were transfected with Foxp3 or suc-
cessive N-terminal truncation mutants of Foxp3 deleting the Proline-
rich domain (Foxp3-C), the zinc-ﬁnger (Foxp3–LZ-FKH), and all do-
mains up to the forkhead (Foxp3–FKH). The FKH domain of Foxp3
was sufﬁcient to associatewithHDAC1. Importantly, HDAC1 association
with Foxp3 was inhibited by theWWRRmutations in the FKH domain,
but not by theWRRmutations (Fig. 4C). Thus theWWRRmutant, which
is defective in modulating gene expression, was unable to associate
with HDAC1 and unable to inhibit intracellular HDAC activity. Thedata suggest that the interaction of HDAC1 with Foxp3 was required
for Foxp3-mediated gene modulation in T cells.
Foxp3 fails to enhance HIV gene expression in human T cells expressing
HDAC1-speciﬁc shRNA
To test the role of HDAC1 in FoxP3-mediated gene regulation, we
ﬁrst tested the effect of inhibiting HDAC1 expression in Jurkat T cells.
Vector or FoxP3-expressing Jurkat T cells were stably transduced with
lentiviral vectors expressing HDAC1-shRNA or control shRNA (N95%
transduction), and infected with VSV-G pseudo-typed HIV-luciferase
reporter virus. Under conditions where HDAC1 levels were knockdown
(~50%, Fig. 5A inset), FoxP3 failed to signiﬁcantly enhance HIV gene ex-
pression in Jurkat T cells expressing the HDAC1-speciﬁc shRNA
(Fig. 5A). Under the same condition, Foxp3 failed to signiﬁcantly inhibit
IL2 gene expression in Jurkat T cells expressing the HDAC1-shRNA (data
not shown). In primary human CD4 T cells, we co-transfected the plas-
mid DNA that express Foxp3, a control shRNA or HDAC1-speciﬁc shRNA
and NL4-luciferase in puriﬁed CD4+ T cells (about 30% transfection as
determined by GFP). The transfected cells were activated and analyzed
for HIV gene expression. Either Foxp3 or HDAC1-shRNA signiﬁcantly
enhanced HIV gene expression. As in Jurkat T cells, Foxp3 failed to
enhance HIV gene expression in primary human T cells with the
HDAC1-shRNA (Fig. 5C). Therefore, Foxp3 interacted with HDAC1
to modulate HIV-1 gene expression in human T cells.
Fig. 3. Foxp3 inhibits HDAC1 activity. (A) Flag-tagged HDAC1–4 are cotransfected into 293 T cells with vector or Foxp3. HDACs were IPed with anti-Flag mAb and HDAC activity was
measured. HDAC1 (but not HDAC2–4) activity is speciﬁcally inhibited by Foxp3 coexpression. Western blots show relative IP of each HDAC and FoxP3 expression. (B) A summary of
3 independent experiments with HDAC1 and HDAC2 in 293 T cells co-transfected with Foxp3. Error bars indicate SD, and * indicates signiﬁcant differences (pb0.05). (C) Foxp3
inhibits HDAC1 activity in Jurkat T cells. Jurkat cells transduced with vector or Foxp3 in the presence or absence of HDAC1 expression were analyzed for HDAC activity. Error
bars indicate SD. * indicates signiﬁcantly lower than vector control, and ** indicates signiﬁcantly higher than control (pb0.05). (D) HDAC1 nuclear levels are unchanged by
Foxp3. Nuclear lysates of Jurkat cells transduced with vector or Foxp3 are assayed for HDAC1 protein levels by western blot for HDAC1, with PARP as controls.
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We report here that Foxp3may function as anHDAC inhibitor to sig-
niﬁcantly enhance HIV or inhibit IL-2 gene expression in T cells. HDACi
TSA failed to enhance HIV-1 gene expression in Foxp3-expressing
T cells. We found that human CD4+CD25+ Treg had lower levels of
HDAC activity than CD4+CD25− Th cells, and ectopic expression of
Foxp3 in Jurkat T cells also resulted in a decrease in cellular HDAC activ-
ity. Foxp3 speciﬁcally inhibited HDAC1 when coexpressed in 293 T or
Jurkat T cells, correlated with association of Foxp3 and HDAC1. Critical
residues in the forkhead domain of Foxp3were required for HDAC inhi-
bition, association and HIV activation by Foxp3. Finally, we report that
Foxp3 failed to signiﬁcantly enhance HIV gene expression in human
T cells with reduced HDAC1 expression.
HDAC inhibitor TSA has been proposed to relieve LTR repression
by increased acetylation of histones and “relaxing” the chromatin to
enhance gene expression (Laughlin et al., 1993; Steger et al., 1998;
Van Lint et al., 1996). Binding of Foxp3 to target promoters is associ-
ated with changes in histone acetylation (Holmes et al., 2007; Wu
et al., 2006). Thus, Foxp3 inhibition of HDAC1 may increase LTR his-
tone acetylation. However, several reports have shown that HDACi
can either activate (Chen et al., 2001; Quivy et al., 2002) or repress
(Rahman et al., 2003; Yin et al., 2001) NFκB activity depending on the
cell type and the context of the promoter environment. TSA-mediated
activation of the HIV LTR also requires the NFκB binding sequences.
We demonstrate that Foxp3 enhances HIV-1 LTR through an NFκB-
dependent mechanism in T cells (Holmes et al., 2007). Foxp3 may in-
hibit HDAC1 tomodulate the activity of NFκB at the LTR promoter, likely
in cell type-, cell activation condition- and promoter-speciﬁc fashions.It has been reported that Foxp3 can inhibit HIV LTR activity via the
NFκB/NFAT sites (Grant et al., 2006; Selliah et al., 2008). The discrep-
ancy between different reports regarding Foxp3 modulation of HIV
gene expression may be due to differences in activation conditions
and in speciﬁc experimental systems. Infection of resting T cells or acti-
vation following HIV-1 infection of resting T cells show Foxp3 enhance-
ment of HIV gene expression (this report and (Holmes et al., 2007)). In
contrast, Foxp3 in T cells activated prior to HIV-1 infection appears to
lead to inhibition of HIV replication by Foxp3 (Grant et al., 2006; Selliah
et al., 2008). This is consistent with our recent ﬁnding that HIV-1 pref-
erentially infects and replicates in Foxp3+ T cells in humanized
mouse model in vivo (Jiang et al., 2008), where human T cells are not
activated prior to HIV-1 infection.
Although HDAC activity has been proposed to be involved in Treg
cell function, no link has been established between Foxp3 and HDCA1.
A HAT/HDAC complex including Foxp3/Tip60/HDAC7 is required for
IL-2 repression by Foxp3 (Miller-Jensen et al., 2007); but it is not clear
if Foxp3 modulates the activity of HDAC7. In addition, mouse CD4+
CD25+ Treg cells have higher HDAC9 expression than CD4+25−
cells; and Treg cells from HDAC9−/− mice are more suppressive,
pointing towards a role of this class II HDAC in Treg function (Tao
et al., 2007). It is likely that mouse Treg cells are distinct in HDAC ex-
pression from human Treg cells.
The biochemical mechanism by which Foxp3 inhibits HDAC1 ac-
tivity is currently unclear. Our results showed that Foxp3 was associ-
ated, directly or indirectly, with HDAC1 in T cells (Fig. 4). However,
co-expression of the two proteins by in vitro transcription-translation
failed to demonstrate either direct binding or inhibition of HDAC1 activ-
ity by Foxp3 (D. Holmes and L. Su, Unpublished results). Since the
Fig. 4. Foxp3 interacts with HDAC1. (A) 293 T cells cotransfected with ﬂag-HDAC1 andmyc-tagged Foxp3were Immunoprecipitated with anti-Flag antibody. (B) Jurkat cells transduced
withmyc-Foxp3were Immunoprecipitatedwith anti-myc antibody and probed for endogenous HDAC1. (C) Forkheadmutation ablates Foxp3:HDAC1 interaction. 293 T cells were trans-
fected with myc-Foxp3 mutants with deletion or point mutations and Flag-HDAC1. HDAC1 was immunoprecipitated with anti-Flag antibody and Foxp3 was visualized by western blot.
Total 10% of input cell lysate was included as controls. ZF-LZ-FKH, Myc-tagged FoxP3 with the N-terminal 177 amino acids deleted; LZ-FKH, Myc-tagged FoxP3 with the N-terminal 230
amino acids deleted; FKH, Myc-tagged FoxP3with the N-terminal 311 amino acids deleted;WRR andWWRR are full-length FoxP3mutants with point mutations in the FKH domain (5).
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we can rule out regulation of HDAC1 expression, stability or nuclear
translocation by Foxp3. HDAC activity is regulated by posttranslationalFig. 5. Foxp3 fails to enhance HIV gene expression in human T cells with reduced HDAC1 exp
with shRNA-HDAC1 (shHDAC1) or non-speciﬁc shRNA control (shNS) vector transduction (
(relative to PARP, inset). Cells were then infected with VSV-G pseudo-typed NL-4 luciferase
are representative of at least 3 independent experiments each done in triplicate. *pb .05, u
HDAC1 shRNA or a control shRNA, and with Foxp3 and the NL4-luciferase reporter provirus
tion and HIV gene expression was measured by luciferase expression at 4–5 days post trans
resentative experiment in triplicates. Three independent experiments were performed withmodiﬁcation, association with multi-subunit complexes, and cofactor
availability (Sengupta and Seto, 2004). Foxp3 is associated with a
large molecular weight complex that includes Brg-1 and MBD3,ression. (A) Jurkat T cells were transduced with FoxP3 gene or control vector, followed
both N90% frequency). Western blot showed about 50% inhibition of HDAC1 expression
virus and HIV gene expression was measured by luciferase expression. Results shown
sing Student t-test. (B) Primary human resting CD4+ T cells were nucleofected with
. Transfected cells were stimulated with anti-CD3/CD28 mAb at 3–4 days post transfec-
fection. HIV-directed luciferase gene expression is shown. Data are derived from a rep-
similar results. *pb0.05 compared to vector controls.
17D. Holmes et al. / Virology 421 (2011) 12–18components of the SWI/SNF and Mi2/NuRD complex respectively (Li et
al., 2007). The Mi-2/NuRD complex also contains HDAC1, suggesting
that FoxP3 may alter HDAC1 activity in association with speciﬁc com-
plexes. It will be of future interest to elucidate the biochemical mecha-
nism by which Foxp3 inhibits HDAC1 activity in association with
HDAC1-containing complexes.
Materials and methods
Plasmids, cells and antibodies
FoxP3 and deletion mutants in the HSPG retrovirus vector, and
IL2-promoter driven luciferase were cloned as previously described
(Holmes et al., 2007). Flag-tagged HDAC1–4 plasmids were provided
by Dr. Tso-Pang Yao at Duke University. Foxp3 mutants WRR and
WWRR were a kind gift from Dr. Ajana Rao at Harvard Medical School
(Wu et al., 2006). The NL4-luc-R-E- reporter plasmid was provided by
Dr. N. Landau at NYU (15). Jurkat cells were maintained in RPMI 1640
(Gibco BRL), 293 T cells were maintained in DMEM and primary
human T cells were maintained in Iscoves MEM, supplemented with
10% FBS (Sigma), 2 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml Streptomycin. CD4+ primary T cells were puriﬁed from
Ficoll separated PBMC by negative selection (N95% purity) (MACS
human CD4+ T cell isolation kit) and CD4+CD25+ Regulatory
T cells were puriﬁed by MACS human Regulatory T cells isolation kit
(Miltenyi-Biotech, Auburn, CA). CD4+CD25+ cell purity wasN95%.
T cells were activated by anti-CD3/CD28 mAb cross linked by plate-
bound anti-mouse IgG as reported (Holmes et al., 2007). Antibodies
used in Western Blot include anti-Flag M2 (Sigma), anti-myc mono-
clonal 9E10 and anti-HDAC1 polyclonal rabbit antibody (Santa Cruz).
Retrovirus production and transduction
293 T cells were co-transfected with retroviral vector, VSV-G and
gag/pol containing plasmids as described (Cofﬁeld et al., 2003). For
retroviral transduction, Jurkat cells were spin-inoculated with retro-
viruses for 3 hours at 5,500 rpm with polybrene (8 μg/ml). Transduc-
tion of N95% efﬁciency was obtained as measured by GFP expression.
Transduction of Jurkat T cells and luciferase assay
For production of single cycle HIV-Luc reporter virus, 293 T cells
were transfected with VSV-G and NL4-HIV-Luc (He and Landau,
1995) plasmids by Effectene (Qiagen, Valencia, CA). Jurkat cells
were transduced with the VSV-g HIV-luciferase reporter viruses.
Brieﬂy, cells previously transduced with vector or Foxp3 were
infected with NL4-luciferase reporter virus. At 24 hours post infec-
tion, Jurkat cells were activated with anti-CD3/CD28 for 24 hours.
Cells were lysed in 1× reporter lysis buffer (promega) and luciferase
expression was determined by Luciferase Assay System (Promega).
Experiments were done in triplicates and repeated at least three times.
293 T cell transfection, immunoprecipitation and Western Blot
293 T cells were transfected and fractionated into cytoplasmic and
nuclear lysates and quantitated by BCA protein assay kit (Pierce).
500 μg nuclear lysates were incubated overnight with 2 μg anti-Flag
antibody followed by Protein A bead incubation. For HDAC assay,
the immunoprecipitated complex was washed 3× with PBS and
HDAC activity was analyzed by Flour De Lys HDAC assay with HDAC
substrate in HDAC assay buffer for 30 minutes at 37 °C and developed
(Biomol, Plymouth Meeting, PA). For Western, FoxP3 was probed
with an anti-FoxP3 antiserum (Jiang et al., 2006) followed by secondary
α-rabbit–IgG–HRP (1:10,000) (Amersham Biosciences) and visualized
by ECL (Amersham Biosciences).Flourimetric cellular HDAC activity assay
Jurkat or primary T cells were incubated with Flour de lys intracel-
lular HDAC substrate for 2 hours at 37 °C. For HDAC assay in primary
T cells, puriﬁed CD4 Th or Treg cells were stimulated for 2–5 days and
assayed under similar conditions as Jurkat T cells. Experiments were
done in triplicate and are repeated 3 times.
Primary T cell puriﬁcation and transfection
CD4+ primary T cells were puriﬁed from Ficoll separated PBMC by
MACS human CD4+ T cell isolation kit (N95% purity, Miltenyi-
Biotech, Auburn, CA). Puriﬁed primary CD4+ T cells were transfected
by Amaxa nucleofector kit (Amaxa Biosystems, Gaithersburg, MD).
Brieﬂy, 5×106 unstimulated CD4+ T cells were transfected with
5 μg plasmid DNA (20–40% efﬁciency by GFP expression), and cultured
for 48 hours before activation by CD3 and CD28 crosslinked with plate-
bound IgG. Cells were activated for 48 hours and HIV driven or IL2 drive
luciferase was measured.
Statistical analysis
For statistical analysis, a two-tailed Student t-test was employed
where pb0.05 was considered signiﬁcant.
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